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Background: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies in humans, and its
prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of
HCC; however, the molecular mechanisms that lead to hepatocarcinogenesis and progression are still not clearly
understood.
Methods: The expression of DACT2 in specimens from 30 paired HCCs and an additional 61 HCC patients after liver
transplantation was evaluated by quantitative RT-PCR and immunohistochemical analysis. We investigated the
methylation status of the DACT2 promoter region. We also analyzed the alterations of the cell cycle, migration and
invasion after DACT2 knockdown.
Results: The expression level of DACT2 was significantly lower in HCC tissues than in non-cancerous tissues.
Reduced DACT2 expression was associated with large tumor size. DACT2 transcripts were at low levels in
hypermethylated liver cancer cells and were restored by exposure to a demethylating agent. Reduced expression of
DACT2 in MHCC97L cells induced G1/S arrest, increased cell proliferation, and promoted cell invasion.
Conclusions: Our study suggests that DACT2 is silenced by promoter hypermethylation, and reduced DACT2 can
promote liver cancer progression. DACT2 may serve as a novel tumor suppressor gene in HCC.
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Primary liver cancer, predominantly consisting of hepato-
cellular carcinoma (HCC), is the fifth most common can-
cer and the third most common cause of cancer-related
deaths worldwide. It is estimated that approximately
626,000 new cases of HCC occur annually and nearly as
many deaths [1,2]. Cases in China account for more than
50% of the world’s cases because of the high prevalence of
chronic hepatitis B virus infection and liver cirrhosis [3,4].* Correspondence: zyzss@zju.edu.cn
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reproduction in any medium, provided the orHCC is one of the most aggressive malignancies in
humans, and its prognosis is generally poor even after sur-
gery [5-7]. Many advances have been made to understand
the pathogenesis of HCC; however, the molecular mecha-
nisms leading to hepatocarcinogenesis and progression are
still not clearly understood. Therefore, we are still lacking
effective therapies of HCC. For better diagnosis and treat-
ment of HCC, it is crucial to identify the genes responsible
for the initiation, promotion, and progression of the di-
sease. A detailed understanding of the molecular mecha-
nisms associated with HCC ultimately could improve our
current treatment modalities of this disease. HCC is a
highly aggressive cancer with activation of multiple signal
transduction pathways and various gene alterations [8-10].
The Wnt signaling pathway has been shown to be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the 61 patients and relationship
of DACT2 expression with clinicopathological parameters
in HCC
Variables DACT2 expression
Low (n = 31) High (n = 30) P value*
Age (years)
≤50 17 18 0.797
>50 14 12
Gender
Female 1 4 0.195
Male 30 26
PVTT
Negative 21 19 0.791
Positive 10 11
Preoperative AFP level (ng/ml)
≤400 15 18 0.444
>400 16 12
Histopathologic grading
Well + moderate 24 19 0.270
Poor 7 11
Tumor size (cm)
≤5 9 17 0.040
>5 22 13
Tumor number
Single 10 10 1.000
Multiple 21 20
PVTT, portal vein tumor thrombi; AFP, alpha-fetoprotein.
*Chi-square test (Fisher’s exact test).
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motility [11]. This pathway is deregulated in a number of
cancers, including HCC [12]. Dapper, antagonist of beta-
catenin, homolog 2 (DACT2), located on chromosome
6q27, belongs to the DACT (Dpr/Frodo) gene family. This
family consists of DATC1, 2 and 3 [13,14]. Members of
the DACT (Dpr/Frodo) gene family have been shown to
modulate Wnt/β-catenin signaling by interacting with
Dishevelled (Dvl), a central component of Wnt signaling
[15-17]. A number of studies have revealed the biological
properties of DACT proteins in human cancer. For ex-
ample, Yau et al. demonstrated that the expression of
HDPR1, the human homolog of Dpr, was frequently and
significantly downregulated in HCC. Downregulation of
HDPR1 frequently occurs through hypermethylation of
the promoter region and allelic loss of the locus [18]. Jiang
et al. identified DACT3 as an important negative regulator
of Wnt/β-catenin signaling and functions as a potential
tumor suppressor in colorectal cancer. The expression of
DACT3 is consistently suppressed in colon cancer, and its
expression is silenced by bivalent histone modification
[19]. DACT2 has been described and studied in both fish
and mammals [14,20,21]. Although there have been rela-
tively few reports about DACT2 in cancer research, the
expression level of DACT2 appears to be reduced in some
colorectal tumors. To our knowledge, there have been no
studies investigating a possible correlation among the
expression of DACT2, the clinicopathological factors
in HCC, and the relevance of DACT2 expression to
oncogenesis.
In this study, we explored DACT2 gene expression in
HCC and its possible association with clinicopathological
factors. In addition, the epigenetic regulation of DACT2 in
HCC cells was also analyzed.
Methods
Study population and tissue samples
Sixty-one HCC patients who had undergone liver trans-
plantation during 2003 and 2005 at our hospital (First
Affiliated Hospital, Zhejiang University School of Medi-
cine, Zhejiang, China) were enrolled in this study. The
study was approved by the local ethics committee, and
informed consent was obtained from all of the patients.
Of these patients, HCC was diagnosed either before or
after transplantation, which was confirmed by histo-
pathological examination. Complete clinical and labora-
tory data were available before operation and during
follow-up, and all patients were HBV-positive (HBsAg+).
Distribution of clinicopathological data in the study
cohort is given in Table 1. An additional 30 patients with
HCC were also included in the present study. Specimens
of cancer tissues and adjacent noncancerous tissues were
collected from these patients after obtaining informed
consent.Reverse-transcription PCR and real-time reverse-transcription
PCR
Total RNA was extracted from hepatic specimens or cell
lines, and cDNA was synthesized from total RNA. The
messenger RNA (mRNA) expression level of theDACT2
was determined by RT-PCR. The polymerase chain reac-
tion (PCR) primer sequences for the DACT2 mRNA
amplification have been described previously [19]. Real-
time PCR reactions were performed by the ABI7500 sys-
tem (Applied Biosystems, CA, USA) and SYBR green
dye (Applied Biosystems).
Immunohistochemistry
Immunohistochemical studies of DACT2 were performed
on surgical specimens from HCC patients with cancerous
and noncancerous adjacent tissues. Primary rabbit poly-
clonal antibodies against DACT2 (ProSci Inc., CA, USA)
were used at a dilution of 1:600. Immunohistochemistry
was performed as described previously [22].
Cell lines
Liver cancer cell lines SMMC-7721, HepG2 and Hep3B
as well as the metastasis-capable human HCC cell lines
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China) and HCCLM3 (Liver Cancer Institute of Fudan
University, Shanghai, China) were purchased. All cell
lines were maintained in the recommended culture con-
dition and incubated at 37°C in a humidified environ-
ment containing 5% CO2.
Bisulfite modification of DNA
Genomic DNA was extracted from cell lines using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
DNA samples were modified using EZ DNA Methyla-
tion Golden Kit (Zymo Research, CA, USA). Bisulfite
converts unmethylated CpG sites to UpG without modi-
fying methylated sites.
Demethylation with the DNA demethylating agent
5-Aza-20-deoxycytidine
Liver cancer cells were plated at a density of 5 × 104
cells/ml. After 24 h, cells were treated with 10 μmol/l of
the DNA demethylating agent 5-aza-20deoxycytidine
(5-aza-dC) (Sigma-Aldrich, St. Louis, MO, USA) for
96 h. DNA and RNA were then extracted from cells.
MSP and bisulfite genomic sequencing
The methylation status of the DACT2 CpG islands was
determined by MSP. The primers for detection of the
methylated and unmethylated DACT2 CpG islands were
described in the previous study [19]. For bisulfite ge-
nomic sequencing, 2 μl of bisulfite-treated DNA was
amplified using primers [19]. The PCR products were
cloned into a PUCm-T vector. Three to five colonies
were randomly chosen and sequenced for plasmid DNA
extraction with QIAprep Spin Miniprep Kit (Qiagen,
Hilden, Germany).
RNA interference
Short interfering RNA (siRNA) duplexes (GenePharma,
Shanghai, China) were used to downregulate DACT2 ex-
pression, and a nonsilencing siRNA was used as negative
control. After growth in the plate for 24 h, cells were
transfected with 33 nM siRNA using Lipofectamine 2000
transfection reagent (Invitrogen, CA, USA) according to
the manufacturer’s instructions. The efficacy of transfec-
tion was checked by real-time PCR after 48 h.
Cell cycle analysis
MHCC97L cells were transfected with DACT2 siRNA
or a negative control. After 48 h, cells were harvested
and stained with a DNA PREP kit (Beckman Coulter,
Fullerton, CA). The percentage of cells in G0/G1, S,
and G2/M phase was quantified using flow cytometry
analysis according to the manufacturer’s instructions
(Cytomics FC 500, Beckman Coulter). Analysis of cell
cycle data was performed with Multicycle (Los Angeles,CA) analysis software. All experiments were completed in
triplicate.
Cell invasion and motility assay
Cell invasion analysis was performed using 24-well
transwell plates (Millipore, Billerica, MA). Forty-eight
hours after RNA interference, the filters were coated
with Matrigel (BD Bioscience, San Jose, CA) in the
upper compartment and seeded with 200 μl of 0.8 × 105
cells. The lower compartment was filled with cell culture
medium supplemented with 15% fetal bovine serum.
After 48 h, migrated cells on the bottom surface were
fixed with methanol and stained with 0.1% Crystal Vio-
let. The cell motility assay was performed similarly, ex-
cept the cells were applied into the uncoated filter and
incubated for 24 h. The invading cells were examined,
counted, and photographed using digital microscopy.
Three fields were counted per filter in each group.
Statistical analysis
The relationship between DACT2 expression and clinico-
pathological variables were assessed by the chi-square test.
The detailed statistical tests used in the study are shown
in Results and in the table and figure legends. P < 0.05 was
considered statistically significant.
Results
Analysis of DACT2 expression in clinical samples
Expression of DACT2 mRNA in HCC tumor specimens
was lower than in nontumoral liver specimens in 24 of the
30 paired cases. The average level of DACT2 mRNA
expression in HCC tissues was 2.25-fold lower than in
adjacent noncancerous tissues (4.68 ± 6.96 vs. 10.55 ±
14.6; P < 0.05) as shown in Figure 1A. DACT2 protein
expression was also investigated by immunohistochemis-
try in tumor tissues and the nontumoral liver counterparts
(n = 26), as is shown in Figure 1B,C,D. In healthy liver tis-
sues, DACT2 was almost homogeneously expressed in
non-neoplastic hepatocytes. In tumor tissues, two staining
patterns could be distinguished. In most patients (21/26
cases), DACT2 expression was markedly decreased in
tumor tissues compared with nontumorous liver tissues.
Only five samples showed comparable expression levels
of DACT2 between tumor and noncancerous liver
specimens.
Correlation of DACT2 expression with clinicopathological
parameters
In this study, we also included another cohort of 61
HCC patients who had undergone liver transplan-
tation. We divided them into two expression groups.
The low-expression group (30 samples) included pa-
tients whose tumor tissue expressed DACT2 mRNA
below the median level. The high-expression group
Figure 1 (A) DACT2 mRNA expression in 30 pairs of clinical samples. The expression level of DACT2 mRNA was quantitatively determined
by RT-PCR for tumor tissue specimens and its corresponding nontumor tissue specimens. The mean expression level of DACT2 in each group was
indicated (*P < 0.05, Student’s t-test). Representative immunohistochemical staining of DACT2 protein in liver cirrhosis tissue (B) and
hepatocellular carcinoma section (C) and low expression of DACT2 in tumor at the tumor-normal interface (D) (original magnification, ×10).
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expressed DACT2 mRNA above the median value. Clini-
copathological parameters are listed in Table 1 in relation
to DACT2 mRNA expression status. In the relationship
between DACT2 expression and the clinicopathological
data, we found that DACT2 expression was negativelyFigure 2 (A) DACT2 mRNA expression and its methylation status in li
after treatment with 5-Aza. Demethylation was observed in the HepG2 cell
several liver cancer cell lines was examined by bisulfite genomic sequencincorrelated with tumor size (P = 0.04). Tumors with low
DACT2 expression were significantly larger in size
(>5 cm) than those with high expression. There was no
statistically significant correlation between DACT2
expression and age, gender, AFP, histopathological gra-
ding, or tumor number.ver cancer cell lines. (B) The mRNA expression of DACT2 was restored
line after treatment with 5-Aza, and the methylation of DACT2 in
g.
Figure 3 Effect of DACT2 knockdown on cell cycle distribution of HCC cell line. (A) Real-time PCR analysis showing expression of DACT2 in
MHCC97L cell was significantly reduced after treatment with DACT2 siRNA compared with negative siRNA (*P < 0.01, Student’s t-test). (B) Cell
cycle distribution of MHCC97L cell treated with DACT2 siRNA (lower) or negative control (upper). (C) The alteration of cell cycle distribution was
different significantly (*P < 0.01, Student’s t test). All assays were performed in triplicate wells.
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liver cancer cells
We first detected the expression level of DACT2 in five
liver cancer cell lines. The results showed that DACT2
transcript was silenced or reduced in HepG2 and HCCLM3
cells (Figure 2A). To examine the role of promoter methy-
lation in the silencing of DACT2, we further analyzed the
methylation status of the DACT2 gene; the results indicate
that the DACT2 gene promoter was partially methylated in
cell lines with reduced or silenced expression (Figure 2A).
To demonstrate whether methylation mediates DACT2 si-
lencing, we treated two methylated cell lines that showed
silencing of DACT2 with 5-Aza. 5-Aza restored DACT2
expression in both cell lines with obvious demethylation
observed in the treated HepG2 cell line by bisulfite genomic
sequencing (Figure 2B), suggesting that DNA methylation
plays a crucial role in the transcriptional silencing of
DACT2 in liver cancer cells.Cell cycle alterations after DACT2 silencing
As shown in Figure 3A, the inhibitory efficiency of
siRNAs for gene transcription was significant in morderate-
metastasic potential MHCC97L cells. To determine the role
of DACT2 in tumor cell cycle progression and tumor cell
proliferation, we examined the effect of DACT2 knock-
down in MHCC97L cells on the cell cycle. After 48 h of
transfection, cell proliferation as determined by the number
of cells in the S phase was increased from 25.9% to 34.6%
(P < 0.01), as is shown in Figure 3B,C. Moreover, the num-
ber of cells in the G0/G1 phase decreased from 61.7% to
50.5% (P < 0.01).
DACT2 silencing promotes cell migration and invasion
The effect of DACT2 on the migration and invasiveness of
HCC cells was analyzed using the Matrigel model. We
found that the average number of migratory and invaded
cells transfected with DACT2 siRNA was significantly
Figure 4 Alteration of DACT2 expression in MHCC97L cell changes its migration and invasiveness in vitro. (A) Representative images of
migration and invasiveness of MHCC97L cell transfected with negative siRNA or siRNA against DACT2 (original magnification, ×10). (B) Selective
knockdown of DACT2 led to a significant increase of migratory and invasive ability in MHCC97L (*P < 0.01, Student’s t-test). The columns indicate
the number of migrated or invaded cells per field (original magnification, ×20).
Gao et al. World Journal of Surgical Oncology 2013, 11:57 Page 6 of 8
http://www.wjso.com/content/11/1/57increased when compared to those with negative control
siRNA (Figure 4), indicating that the invasive potential of
MHCC97L cells increased after DACT2 knockdown. This
suggests that DACT2 also influences the migration and in-
vasiveness of HCC cells.Discussion
In the current study, we found that the expression level
of DACT2 was downregulated in human hepatocellular
carcinoma by quantitative RT-PCR and immunohisto-
chemical analysis. Similarly, in a previous study, Jiang
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in some colorectal tumors [19]. Therefore, DACT2 was
implicated as a tumor suppressor gene in some types of
human cancers. We further speculate about whether the
expression level of DACT2 might be associated with
clinicopathological parameters in liver transplantation
HCC patients. Clinicopathological analysis revealed that
HCC patients with low DACT2 expression was corre-
lated with a larger tumor size (>5 cm) than those with
high DACT2 expression. DACT2 may thus play a critical
role in the proliferation and progression of HCC cells.
To the best of our knowledge, there have been no prior
reports studying the associations between DACT2 gene
expression and clinicopathological parameters in human
cancer. Thus, this is the first study to determine the ex-
pression pattern of DACT2 and report the clinical sig-
nificance of DACT2 gene expression in HCC. Because of
the possible role of DACT2 in tumor suppression and
its reduced expression in cancer, the correlation of
DACT2 expression and its methylation status have been
characterized in colorectal cancer. Aberrant promoter
hypermethylation of DACT2 was detected in several
tumor samples with reduced DACT2 expression [19].
This finding led us to investigate the potential correl-
ation of expression level and promoter methylation of
DACT2 in HCC. Similar to the previous report on colon
cancer cells, we found that DACT2 expression was
present at very low or undetectable levels in some HCC
cell lines and that 5-Aza-dC restored the transcription
level of DACT2 (Figure 3). These data suggested that
the downregulation of DACT2 expression was closely
associated with promoter hypermethylation in vitro.
Taken together, these findings further support that
DACT2 is inactivated epigenetically in a number of hu-
man solid tumors including HCC and that promoter
hypermethylation may be a critical mechanism for the
transcriptional silencing of the DACT2 gene in liver can-
cer cell lines.
The tumor-suppressive function of DACT2 in HCC
was investigated further by in vitro assays. In DACT2
expression silenced MHCC97L cells, FACS analysis
revealed a significant increase of S phase cells and a
decrease of G0/G1 phase cells, indicating G1/S arrest of
the cell cycle and a significant promotion of cell prolife-
ration. In addition, DACT2 knockdown in MHCC97L
cells also resulted in increased ability of tumor cell inva-
sion and metastasis (Figure 4). Taken together, these
results suggest the role of DACT2 as a functional tumor
suppressor gene through suppressing tumor cell prolife-
ration, migration and invasion in HCC.
Our studies are the first to clearly identified the bio-
logical functions of DACT2 in human HCC cells; how-
ever, the molecular basis for how DACT2 knockdown
leads to increased proliferation and invasion in HCC isstill unknown. A number of studies have tried to illu-
minate the molecular mechanisms of the Dapper family
proteins in regulating cell behavior. Waxman et al. found
that zebrafish Dpr2 is a vital regulator of the
noncanonical Wnt/Ca2+−PCP pathway [23]; however,
Su et al. suggested that mouse Dpr2 inhibits the Wnt/
JNK pathway and functions as a negative regulator of
the TGF-β/Nodal signal pathway [24]. Thus, the Dpr2
protein may function to regulate distinct cell signaling
pathways in a context-dependent manner. Therefore, the
molecular mechanisms by which DACT2 exerts the
tumor-suppressor effect in HCC needs further study.
It should be noted that there were some limitations in
the current study. HCC is a tumor of diverse etiology,
and our study population predominantly consisted of
patients with hepatitis B-induced HCC. It is therefore
important to determine whether DACT2 still functions
as a tumor suppressor gene in patients with other under-
lying liver diseases. In addition, the study was confined
to the Han Chinese population, which should be taken
into account when evaluating the potential applicability
of our findings to other ethnic populations. Lastly, the
sample size was small because of the strict eligibility of
the study population. The study should therefore be
viewed as hypothesis generating, and our findings should
be confirmed by examining larger clinical samples.
Conclusion
We demonstrate that expression of DACT2 is down-
regulated in HCC compared to adjacent healthy liver tis-
sues and that reduced DACT2 expression is significantly
correlated with large tumor size. Furthermore, promoter
hypermethylation is the principal regulatory mechanism
of DACT2 inactivation in HCC cells. Functionally,
DACT2 is an important tumor suppressor gene with key
roles of regulating tumor cell proliferation, migration
and invasion in the development and progression of
HCC. Our study suggests that DACT2, which was si-
lenced by promoter hypermethylation, may serve as a
novel candidate tumor suppressor gene in HCC.
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